AT
ATTO.US Attovia Therapeutics, Inc. Common Stock
- Market cap
- USD 692M
- P/E
- -
- P/B
- -
- ROE
- -20.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ATTO.US undervalued?
Graham numberThe Graham number of Attovia Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Attovia Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Attovia Therapeutics, Inc. Common Stock yet.
Attovia Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Attovia Therapeutics, Inc. Common Stock
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and…
Full company profileAttovia Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Attovia Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 0.00 | 1.35M | 600K |
| Gross Profit | -313K | 546K | -381K |
| Operating Income | -41.6M | -67.2M | -89.0M |
| EBITDA | -41.2M | -66.4M | -88.1M |
| Net Income | -39.8M | -60.6M | -82.2M |
| EPS | -0.92 | -1.41 | -0.28 |
| Balance Sheet | |||
| Total Assets | 76.7M | 166M | 412M |
| Total Liabilities | 14.6M | 15.1M | 14.1M |
| Shareholders' Equity | 62.1M | 151M | 398M |
| Cash & Short-term Investments | 69.3M | 152M | 396M |
| Total Debt | - | 5.26M | 3.84M |
| Cash Flow | |||
| Operating Cash Flow | -35.0M | -59.2M | -80.8M |
| Capital Expenditure | 1.77M | 2.31M | 504K |
| Free Cash Flow | -36.8M | -61.5M | -81.3M |
| Ratios | |||
| ROE | -64.1% | -40.2% | -20.7% |
| ROA | -51.9% | -36.5% | -19.9% |
| Net Profit Margin | - | -4,490.9% | -13,692.0% |
| Debt to Equity | - | 0.03x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Attovia Therapeutics, Inc. Common Stock dividends
Attovia Therapeutics, Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns Attovia Therapeutics, Inc. Common Stock
- Insiders 11.23%
- Institutions 37.72%
- Public & others 51.06%
- Shares outstanding 45.7M
- Free float 26.3M
Top funds holding ATTO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Federated Hermes Kaufmann Small Cap A | 700K | 1.54% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 700K | 1.54% | 0.00% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 568K | 1.25% | +667.54% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 89.6K | 0.20% | +0.21% | Oct 2026 |
| Fidelity Extended Market Index | 79.4K | 0.17% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 42.3K | 0.09% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 35.0K | 0.08% | 0.00% | Sep 2026 |
| Strategic Advisers U.S. Total Stock | 35.0K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 28.0K | 0.06% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 17.8K | 0.04% | 0.00% | Sep 2026 |
| Wellington Global Hlthcr Eq USD G Ac | 17.8K | 0.04% | 0.00% | Sep 2026 |
| Schwab Total Stock Market Index | 14.3K | 0.03% | 0.00% | Sep 2026 |
| Hartford Healthcare Y | 12.4K | 0.03% | 0.00% | Sep 2026 |
| Schwab US Broad Market ETF™ | 11.3K | 0.02% | 0.00% | Oct 2026 |
| Wellington US Research Eq USD S AccUnH | 10.7K | 0.02% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 10.4K | 0.02% | +730.30% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 9.06K | 0.02% | +713.02% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 6.60K | 0.01% | +640.97% | Sep 2026 |
| Global Atlantic Wellington RsrchMgdRskII | 2.10K | 0.00% | 0.00% | Sep 2026 |
| Hartford Healthcare HLS IA | 1.80K | 0.00% | 0.00% | Sep 2026 |
Top institutions holding ATTO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Sanofi | 1.08M | 2.38% | 0.00% | Sep 2026 |
Attovia Therapeutics, Inc. Common Stock company profile
- Company name
- Attovia Therapeutics, Inc. Common Stock
- Ticker
- ATTO.US
- Exchange
- USA Stocks
- Listed since
- Aug 5, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 44
- Fiscal year end
- December
- Address
- 1091 Industrial Road, San Carlos, CA, United States, 94070
- Phone
- 510 399 5001
- Website
- attovia.com
About Attovia Therapeutics, Inc. Common Stock
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.
Attovia Therapeutics, Inc. Common Stock management
7- Mr. Tao Fu M.B.A., M.S.CEO, President & Director · born 1972
- Dr. Petter Veiby Ph.D.Chief Scientific Officer · born 1965
- Dr. Hubert C. Chen M.D., M.P.H.Chief Medical Officer · born 1969
- Mr. Steven Chan CPAChief Financial Officer · born 1972
- Dr. Hangjun Zhan Ph.D.Chief Technology Officer · born 1960
- Dr. Bora Han Ph.D.VP & Head of Preclinical Development
- Dr. Zaneta Odrowaz Ph.D.Chief Business Officer, Treasurer & Secretary · born 1984